行情

CYAD

CYAD

Celyad Oncology
NASDAQ

实时行情|Nasdaq Last Sale

1.925
+0.375
+24.19%
已收盘, 16:00 05/19 EDT
开盘
1.800
昨收
1.550
最高
1.950
最低
1.800
成交量
2.99万
成交额
4.22万
52周最高
6.40
52周最低
1.510
市值
4,349.34万
市盈率(TTM)
-0.9962
分时
5日
1月
3月
1年
5年
暂无数据
暂无数据
了解CYAD最新的财务预测,通过CYAD每股收益,每股净资产,每股现金流等数据分析Celyad Oncology近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

25.00%强力推荐
25.00%买入
50.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测CYAD价格均价为10.57,最高价位13.09,最低价为8.05。
最高13.09
均价10.57
最低8.05
现价1.925
EPS
实际EPS
预期EPS
-1.07-0.80-0.54-0.27
2020/06
2020/12
2021/06
2021/12
2022/06
机构持股
总机构数: 15
机构持股: 661.94万
持股比例: 29.30%
总股本: 2,259.40万
类型机构数股数
增持
1
1.08万
建仓
6
657.16万
减持
3
2,054
平仓
3
14.84万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.00%
制药与医学研究
+0.51%
高管信息
Chairman/Director
Michel Lussier
Chief Executive Officer/Chief Financial Officer/Executive Board/Director
Filippo Petti
Chief Human Resource Officer/Executive Board
Philippe Nobels
Chief Scientific Officer/Executive Board
David Gilham
Vice President/Executive Board
Fredrik Lehmann
Other
Charles Morris
Executive Board/Secretary
Philippe Dechamps
Executive Board
Stephen Rubino
Non-Executive Director
Chris Buyse
Non-Executive Director
Rudy Dekeyser
Non-Executive Director
Serge Goblet
Independent Director
Maria Koehler
Independent Director
Dominic Piscitelli
Independent Director
Marina Udier-Blagovic
Independent Director
Hilde Windels
暂无数据
暂无数据
CYAD 简况
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

微牛提供Celyad Oncology SA(NASDAQ-CYAD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CYAD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CYAD股票基本功能。